> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-148/
- Published: 2017-09-10T12:00:00.000Z
- Updated: 2026-09-14T22:48:03.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139590

[**FDA Seeks Comments on Reducing Regulation Burden**](https://www.fdaweb.com/fda-seeks-comments-on-reducing-regulation-burden/)  
*Federal Register* multiple notices: FDA seeks comments to help it identify existing regulations and related paperwork requirements that could be modified, repealed, or replaced to achieve meaningful burden reduction. 09/08/2017

[**Workshop on Self-collection Devices for Pap Testing**](https://www.fdaweb.com/workshop-on-self-collection-devices-for-pap-testing/)  
*Federal Register* notice: FDA announces a 1/11/2018 public workshop entitled “Self-Collection Devices for Pap Test” that will obtain feedback about self-collection devices for cervical samples for Pap testing. 09/08/2017

[**Guidance on Tissue/Cell Therapy Deviation Reporting**](https://www.fdaweb.com/guidance-on-tissue-cell-therapy-deviation-reporting/)  
*Federal Register* notice: FDA makes available a guidance on “Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR part 1271.” 09/07/2017

[**Workshop on CDER Rare Disease Drug Development**](https://www.fdaweb.com/workshop-on-cder-rare-disease-drug-development/)  
*Federal Register* notice: FDA announces a 10/30 public workshop entitled “CDER Rare Diseases Public Workshop: Strategies, Tools, and Best Practices for Effective Advocacy in Rare Diseases Drug Development.” 09/07/2017

[**Guidance on Interoperable Medical Devices**](https://www.fdaweb.com/guidance-on-interoperable-medical-devices/)  
*Federal Register* notice: FDA makes available a guidance on “Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices.” 09/06/2017

[**Public Meeting on Grandfathered Dietary Supplements**](https://www.fdaweb.com/public-meeting-on-grandfathered-dietary-supplements/)  
*Federal Register* notice: FDA announces a 10/3 public meeting entitled “Development of a List of Pre-DSHEA Dietary Ingredients.” 09/06/2017

[**Ritalin NDA Not Withdrawn Due to Safety/Effectiveness: FDA**](https://www.fdaweb.com/ritalin-nda-not-withdrawn-due-to-safety-effectiveness-fda/)  
*Federal Register* notice: FDA determines that a Novartis NDA for Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 60 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. 09/06/2017

[**Gynorest Not Withdrawn Due to Safety/Effectiveness: FDA**](https://www.fdaweb.com/gynorest-not-withdrawn-due-to-safety-effectiveness-fda/)  
*Federal Register* notice: FDA determines that a Solvay Pharmaceuticals NDA for Gynorest (dydrogesterone) oral tablets, 5 mg and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. 09/06/2017

[**Draft Guide on REMS eSubmissions**](https://www.fdaweb.com/draft-guide-on-rems-esubmissions-2/)  
*Federal Register* notice: FDA makes available a draft guidance on “Providing Regulatory Submissions in Electronic Format — Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling.” 09/05/2017